Aevi Genomic Medicine Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of AEVI-001 in 22q Deletion Syndrome Genetics Investing
uniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B Genetics Investing
Horizon broadens industry-leading gene editing capabilities through extension of key CRISPR license and grant-funded research Genetics Investing
Predictive Technology Group, Inc. (PRED) Announces Acquisition of US Patent Application for Method for Treating Patients with Stem Cells "Cleaned" via CRISPR Genetics Investing
Fibrocell Announces FDA Fast Track Designation of FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa Pharmaceutical Investing